BR0015149A - Método e composições para administração de taxanos oralmente a pacientes humanos - Google Patents

Método e composições para administração de taxanos oralmente a pacientes humanos

Info

Publication number
BR0015149A
BR0015149A BR0015149-1A BR0015149A BR0015149A BR 0015149 A BR0015149 A BR 0015149A BR 0015149 A BR0015149 A BR 0015149A BR 0015149 A BR0015149 A BR 0015149A
Authority
BR
Brazil
Prior art keywords
taxane
human patients
administered
compositions
orally
Prior art date
Application number
BR0015149-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Samuel Brodor
Kenneth Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of BR0015149A publication Critical patent/BR0015149A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0015149-1A 1999-10-27 2000-10-27 Método e composições para administração de taxanos oralmente a pacientes humanos BR0015149A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16231099P 1999-10-27 1999-10-27
PCT/US2000/029633 WO2001030448A1 (en) 1999-10-27 2000-10-27 Method and compositions for administering taxanes orally to human patients

Publications (1)

Publication Number Publication Date
BR0015149A true BR0015149A (pt) 2002-10-29

Family

ID=22585092

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015149-1A BR0015149A (pt) 1999-10-27 2000-10-27 Método e composições para administração de taxanos oralmente a pacientes humanos

Country Status (18)

Country Link
EP (1) EP1225956A1 (ru)
JP (1) JP2003512443A (ru)
KR (1) KR20030019296A (ru)
CN (1) CN1450923A (ru)
AU (1) AU1104201A (ru)
BR (1) BR0015149A (ru)
CA (1) CA2389583A1 (ru)
CO (1) CO5251425A1 (ru)
CZ (1) CZ20021484A3 (ru)
HU (1) HUP0203303A3 (ru)
IL (1) IL149360A0 (ru)
MX (1) MXPA02004164A (ru)
NO (1) NO20022008L (ru)
PL (1) PL354777A1 (ru)
RU (1) RU2002113659A (ru)
SK (1) SK5822002A3 (ru)
WO (1) WO2001030448A1 (ru)
ZA (1) ZA200203358B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
JP2004536026A (ja) 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
JP2006514698A (ja) * 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
CN101513395B (zh) * 2008-02-20 2011-01-12 单宝华 紫杉醇类双层软胶囊口服制剂药物
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
EP2480208A1 (en) 2009-09-23 2012-08-01 Indu Javeri Methods for the preparation of liposomes
EP2566474B1 (en) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
US20240180888A1 (en) * 2021-03-17 2024-06-06 Dompe' Farmaceutici Spa C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CA2221444A1 (en) * 1996-01-31 1997-08-07 Steven B. Hansel A method of making pharmaceutically active taxanes orally bioavailable
US6025359A (en) * 1996-06-17 2000-02-15 Eli Lilly And Company Drug resistance and multidrug resistance modulators
PL337064A1 (en) * 1997-05-27 2000-07-31 Baker Norton Pharma Method of and compositions for orally administering taxanes to human beings
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
IL138767A0 (en) * 1998-04-01 2001-10-31 Rtp Pharma Inc Anticancer compositions
CA2371912C (en) * 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Also Published As

Publication number Publication date
HUP0203303A2 (hu) 2003-02-28
CN1450923A (zh) 2003-10-22
IL149360A0 (en) 2002-11-10
WO2001030448A1 (en) 2001-05-03
MXPA02004164A (es) 2002-10-17
EP1225956A1 (en) 2002-07-31
NO20022008L (no) 2002-06-19
CO5251425A1 (es) 2003-02-28
CZ20021484A3 (cs) 2003-12-17
PL354777A1 (en) 2004-02-23
HUP0203303A3 (en) 2005-01-28
JP2003512443A (ja) 2003-04-02
CA2389583A1 (en) 2001-05-03
KR20030019296A (ko) 2003-03-06
NO20022008D0 (no) 2002-04-26
ZA200203358B (en) 2003-04-29
AU1104201A (en) 2001-05-08
RU2002113659A (ru) 2004-01-27
SK5822002A3 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
NO20014842D0 (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
BR9809694A (pt) Processo e composição para administração de taxanos oralmente a pacientes humanos
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
RU2007138867A (ru) Режимы дозирования транс-кломифена
CA2321565C (en) L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
KR970061244A (ko) 치매 치료용 약학 조성물
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
ATE454139T1 (de) Arzneimittel mit shikonin als wirkstoff
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
BR9917605A (pt) Composição substituta de plasma
NZ516026A (en) Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/42 (2006.01), A61P 35/00 (2006.01), A61K 3